Investment in Manufacturing

Eli Lilly Chooses Houston for $6.5 Billion Plant to Produce APIs for Orforglipron and Other Drugs

Backed by Texas incentives, the second site in Lilly’s U.S. build-out strengthens onshore drug supply ahead of an orforglipron filing this year.